News

Doxycycline is indicated for a variety of infections when caused by susceptible strains of microorganisms, including respiratory tract and urinary tract infections, skin and skin structure infections, and

Although the trial met its primary efficacy endpoint, the results are disappointing in the context of pivotal trials of Lucentis in monthly dosing regimens that have shown the

Li-Fraumeni syndrome (LFS) is a genetic disorder characterized by inherited mutations in the p53 tumor suppressor gene. This abnormal p53 function is directly addressed by Advexin treatment. “In

Atryn may be given in association with heparin or low molecular weight heparin in these situations. The positive opinion of the advisory board recommends granting market authorization under

The Committee for Medicinal Products for Human Use’s (CHMP’s) positive opinion will now be considered by the European Commission, which is expected to issue a final decision regarding

In July 2005 the FDA issued an approvable letter for Entereg, an investigational drug under review for the management of postoperative ileus (POI) by acceleration of the time

Bristol-Myers Squibb (BMS) will provide Lexicon $20 million in additional research funding over the two-year extended research term which begins in January 2007. The drug target discovery portion

Enzastaurin is an oral serine-threonine kinase inhibitor that is designed to suppress tumor growth through a distinct mechanism of action. In the phase III clinical trial, enzastaurin will

The boards of both companies have approved the transaction, which is expected to close in two months. Financial terms of the transaction were not disclosed. Fumapharm, founded in